Relay Corp - Utang jangka cendhak perusahaan RLAY

The market valuation dynamics for Relay Therapeutics (RLAY) demonstrate the 0.00 metric. Relay Therapeutics (RLAY) develops high-precision medicines using IT solutions for protein modeling, which enables the rapid generation of molecules and cost-effective production. Robotic compound design is supplemented by mandatory medical oversight during trials. Strategic alliances with corporate behemoths ensure business stability by offsetting early-stage research costs.

RLAY: Utang jangka cendhak relaytx.com 04.07.2022 - 28.10.2026

RLAY (Relay Corp): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Bagan rega Relay Therapeutics, Inc.|RLAY - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar Relay Therapeutics, Inc.|RLAY - Nilai Total Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Relay Therapeutics|RLAY - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku relaytx.com|RLAY - Aset Neraca Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Relay Therapeutics|RLAY - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Relay Therapeutics|RLAY - Kewajiban utang agregat|Utang marang nilai buku Relay Therapeutics, Inc.|RLAY - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Relay Therapeutics

Analisis wiwitan perusahaan:RLAY (Relay Therapeutics, Inc.)

For Relay Therapeutics (RLAY), a leader in targeted oncology therapy, the book value of short-term debt reflects the current debt load. This metric aggregates all obligations maturing within one year, measuring immediate solvency. An increase in this indicator signals liquidity risk and instability within the operating cycle. Amid geopolitical barriers and component import challenges, such fluctuations are critical. This chart allows for an objective assessment of the business's financial stability.

Pesaing Relay Therapeutics (RLAY)